Processing

Please wait...

Settings

Settings

1. WO1996005823 - METHODS OF INHIBITING DEMYELINATING AND DYSMYELINATING DISEASES

Publication Number WO/1996/005823
Publication Date 29.02.1996
International Application No. PCT/US1995/010581
International Filing Date 21.08.1995
Chapter 2 Demand Filed 22.02.1996
IPC
A61K 31/38 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
38having sulfur as a ring hetero atom
CPC
A61K 31/38
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
38having sulfur as a ring hetero atom
Y10S 514/903
YSECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
10TECHNICAL SUBJECTS COVERED BY FORMER USPC
STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
514Drug, bio-affecting and body treating compositions
903Multiple sclerosis
Applicants
  • ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center Indianapolis, IN 46285, US
Inventors
  • GLASEBROOK, Andrew, Lawrence; US
Agents
  • LAMMERT, Steven, R.; Barnes & Thornburg 1313 Merchants Bank Building Indianapolis, IN 46204, US
Priority Data
08/294,23822.08.1994US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) METHODS OF INHIBITING DEMYELINATING AND DYSMYELINATING DISEASES
(FR) PROCEDES POUR COMBATTRE LES DEMYELINATIONS ET DYSMYELINATIONS PATHOLOGIQUES
Abstract
(EN)
A method of inhibiting demyelinating or dysmyelinating diseases or their symptoms comprising administering to a human in need thereof an effective amount of a compound having formula (I) wherein R1 and R3 are independently hydrogen, -CH3, (a) or (b), wherein Ar is optionally substituted phenyl; R2 is selected from the group consisting of pyrrolidine, hexamethyleneimino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof.
(FR)
L'invention concerne un procédé pour combattre les démyélinations et les dysmyélinations pathologiques ou leurs symptômes, consistant à administrer à un patient une quantité suffisante pour être efficace d'un composé de la formule (I). Dans cette formule, R1 et R3 sont d'une manière indépendante un hydrogène, un groupe -CH3, (a) ou (b), où Ar est un phényle, éventuellement substitué; R2 est choisi parmi les groupes pyrrolidine, hexaméthylène-imino et pipéridino. L'invention concerne également des sels et des solvates de ces composés acceptables sur le plan pharmaceutique.
Latest bibliographic data on file with the International Bureau